Increased glycated albumin and decreased esRAGE concentrations are associated with in-stent restenosis in Chinese diabetic patients.
BACKGROUND
We investigated the impact of glycated albumin (GA) and endogenous secretory receptor for advanced glycation end products (esRAGE) and RAGE polymorphisms on occurrence of in-stent restenosis (ISR) in Chinese patients with type 2 diabetes.


METHODS
Four hundred nineteen patients with diabetes were divided, based upon the presence or absence of coronary artery disease (CAD) and ISR, into Group I (205 patients without CAD), Group II (128 patients with CAD but without ISR) and Group III (86 patients with ISR). One hundred fifty-two normal subjects were served as controls. Serum concentrations of GA and esRAGE were measured, and RAGE polymorphisms (-374T>A, -429T>C and G82S) were analyzed.


RESULTS
Serum GA concentration was higher and, in contrast, esRAGE concentration was lower in Group III than in the other groups (P<0.05). These two protein concentrations correlated closely with loss index (all P<0.01), and were independent risk factors for ISR in diabetic patients (P=0.01 and P=0.025, respectively). However, there were no differences in the allele and genotype frequencies in the 3 polymorphisms of RAGE gene between groups.


CONCLUSIONS
Increased GA and decreased esRAGE concentrations, but not -374T>A, -429T>C and Gly82Ser polymorphisms of RAGE gene, are associated with ISR in Chinese patients with type 2 diabetes.
Lu
Lin
L
Department of Cardiology, Rui Jin Hospital, Institute of Cardiovascular Diseases, Jiaotong University School of Medicine, Shanghai, People's Republic of China.
Jin Pu
Li
L
Chen
Qiu Jing
QJ
Wang
Linjie
L
Peng
Wenhui
W
Yan
Xiaoxiang
X
Zhang
Qi
Q
Yan Zhang
Rui
R
Gong
Pei Hua
PH
Qiu
Jian Ping
JP
Shen
Wei Feng
WF
D000368:Aged; D002681:China / Q000453:epidemiology; D023903:Coronary Restenosis / Q000097:blood* / Q000150:complications* / Q000453:epidemiology; D048909:Diabetes Complications / Q000097:blood* / Q000453:epidemiology; D005260:Female; D017127:Glycation End Products, Advanced / Q000097:blood*; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D012709:Serum Albumin / Q000378:metabolism*; D015607:Stents; D000093423:Glycated Serum Albumin
D017127:Glycation End Products, Advanced; D012709:Serum Albumin; D000093423:Glycated Serum Albumin